Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.060
+0.170 (5.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.050
-0.010 (-0.33%)
After-hours: Apr 28, 2026, 5:20 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 4.92, with a low estimate of 3.00 and a high estimate of 8.00. The average target predicts an increase of 60.78% from the current stock price of 3.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 10, 2026.
Analyst Ratings
The average analyst rating for Editas Medicine stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +161.44% | Mar 10, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3.5 | Strong Buy | Maintains | $3.5 | +14.38% | Mar 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +63.40% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | +30.72% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +63.40% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
26.59M
from 40.52M
Decreased by -34.37%
Revenue Next Year
18.38M
from 26.59M
Decreased by -30.89%
EPS This Year
-1.05
from -1.80
EPS Next Year
-1.00
from -1.05
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 104.0M | 48.0M | ||||||
| Avg | 26.6M | 18.4M | ||||||
| Low | 3.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 156.5% | 80.4% | ||||||
| Avg | -34.4% | -30.9% | ||||||
| Low | -90.3% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.42 | -0.30 | ||||||
| Avg | -1.05 | -1.00 | ||||||
| Low | -1.33 | -1.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.